Ancient Mind-Body exercise tested to combat chemotherapy muscle loss
NCT ID NCT07709429
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study investigates whether a traditional Chinese mind-body practice called Baduanjin Qigong, combined with standard exercises, can improve muscle strength and quality of life in adults aged 35–55 with colorectal cancer who are undergoing chemotherapy. Participants will take part in supervised sessions three times a week for 12 weeks while continuing their regular treatment. The goal is to find a safe, accessible way to help patients stay stronger and feel better during cancer therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a supervised Baduanjin Qigong exercise program combined with conventional exercises
- What this could lead to
- If it works, this could offer a simple, drug-free way to help colorectal cancer patients maintain muscle strength and feel better during chemotherapy.
- What could go wrong
- This is a small, early-stage trial with only 38 participants, so results may not apply broadly. The benefits of qigong may be modest and hard to separate from the effects of conventional exercise.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 38 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
35 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ranges between 35 and 55 years. * Male \& female patients will participate in the study. * All patients with colorectal cancer undergoing chemotherapy. * All patients enrolled to the study will have their informed consent. * The patients will be instructed to report any side effects during the management. Exclusion Criteria: * Presence Patients with psychological disturbance or mental illness. * Cardiopulmonary disease. * Hypotensive patients. * Nerve, muscle, or joint disease, or other malignant tumors affecting movement. * Autoimmune disease.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Faculty of Physical Therapy, Cairo University
Giza, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ivosidenib plus mFOLFOXIRI and celecoxib as a treatment for BRAF-targeted therapy-refractory BRAF V600E-mutant colorectal cancer patients: a phase II study
- Can a new drug shrink advanced solid tumors?
- Can a new drug shrink tumors that resist standard care?
- A single blood draw to detect five cancers before symptoms appear?
- Can a new drug duo shrink Hard-to-Treat tumors?
- Could a simple mineral calm the Body's Post-Surgery fire?